`
`
`
`BAYER PHARMA AG, BAYER AG and
`JANSSEN PHARMACEUTICALS, INC.,
`
`
`
`
`
`MICRO LABS LTD. and
`MICRO LABS USA INC.,
`
`
`
`
`
`
`
`
`
`Plaintiffs,
`
`
`
`v.
`
`
`
`Defendants.
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`
`
`
`
`
`C.A. No.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`COMPLAINT
`
`
`
`
`
`
`
`
`
`Plaintiffs Bayer Pharma AG, Bayer AG (Bayer AG and Bayer Pharma AG are
`
`collectively referred to herein as “Bayer”), and Janssen Pharmaceuticals, Inc. (“Janssen”) (Bayer
`
`and Janssen are collectively referred to herein as “Plaintiffs”), by their attorneys, for their
`
`Complaint, hereby allege as follows:
`
`NATURE OF THE ACTION
`
`1.
`
`This is an action for patent infringement under the patent laws of the United
`
`States, Title 35, United States Code, that arises out of the submission and amendment by Micro
`
`Labs Ltd. and Micro Labs USA Inc. of an Abbreviated New Drug Application (“ANDA”) to the
`
`U.S. Food and Drug Administration (“FDA”) seeking approval to engage in the commercial
`
`manufacture, use, offer for sale, sale, and/or importation of a generic version of Plaintiffs’ 2.5 mg
`
`XARELTO® product prior to the expiration of U.S. Patent No. 10,828,310 (“the ’310 patent”).
`
`
`
`
`
`Case 1:22-cv-00165-UNA Document 1 Filed 02/04/22 Page 2 of 11 PageID #: 2
`
`
`
`THE PARTIES
`
`Plaintiffs
`
`2.
`
`Plaintiff Bayer Pharma AG is a corporation organized and existing under
`
`the laws of the Federal Republic of Germany, with a place of business at Müllerstrasse 178, 13353
`
`Berlin, Germany.
`
`3.
`
`Plaintiff Bayer AG is a corporation organized and existing under the laws
`
`of the Federal Republic of Germany, with a place of business at Kaiser-Wilhelm-Allee 1,
`
`51368 Leverkusen, Germany.
`
`4.
`
`Plaintiff Janssen Pharmaceuticals, Inc. is a corporation organized and
`
`existing under the laws of the Commonwealth of Pennsylvania, with a principal place of business
`
`at 1125 Trenton-Harbourton Road, Titusville, New Jersey.
`
`Defendants
`
`5.
`
`On information and belief, Defendant Micro Labs Ltd. is a corporation
`
`organized and existing under the laws of India, with a place of business at 27 Race Course Road,
`
`Bangalore 560 001, India.
`
`6.
`
`On information and belief, Defendant Micro Labs USA Inc. is a corporation
`
`organized and existing under the laws of the State of New Jersey, with a place of business at 104
`
`Carnegie Ctr., Suite 216, Princeton, New Jersey.
`
`7.
`
`On information and belief, Defendant Micro Labs USA Inc. is a wholly-
`
`owned subsidiary of Micro Labs Ltd., and is controlled and dominated by Micro Labs Ltd.
`
`8.
`
`On information and belief, Micro Labs Ltd. is in the business of, among
`
`other things, manufacturing, marketing, distributing, offering for sale, and selling generic drug
`
`products. As a part of this business, on information and belief, Micro Labs Ltd., acting in concert
`
`2
`
`
`
`Case 1:22-cv-00165-UNA Document 1 Filed 02/04/22 Page 3 of 11 PageID #: 3
`
`
`
`with Micro Labs USA Inc., files ANDAs with the FDA seeking approval to engage in the
`
`commercial manufacture, use, offer for sale, sale, and/or importation of generic versions of drug
`
`products that are covered by United States patents. On information and belief, as part of these
`
`ANDAs, Micro Labs Ltd., acting in concert with Micro Labs USA Inc., files certifications of the
`
`type described in Section 505(j)(2)(A)(vii)(IV) of the Federal Food, Drug, and Cosmetic Act
`
`(“Paragraph IV Certifications”) to engage in the commercial manufacture, use, offer for sale, sale,
`
`and/or importation of generic drug products prior to the expiration of United States patents that
`
`cover such products.
`
`9.
`
`On information and belief, and consistent with their practice with respect to
`
`other generic products, Micro Labs Ltd. and Micro Labs USA Inc. acted in concert to prepare,
`
`submit, and amend ANDA No. 208334 for Micro Labs Ltd.’s 2.5 mg rivaroxaban tablets (“Micro
`
`Labs’ ANDA Product”), which was done at the direction of, under the control of, and for the direct
`
`benefit of Micro Labs Ltd.
`
`10.
`
`On information and belief, Micro Labs Ltd. and Micro Labs USA Inc. are
`
`agents of each other, and/or operate in concert as integrated parts of the same business group, and
`
`enter into agreements with each other that are nearer than arm’s length, including with respect to
`
`the development, regulatory approval, marketing, sale, offer for sale, and distribution of generic
`
`pharmaceutical products throughout the United States, including into Delaware, and including with
`
`respect to Micro Labs’ ANDA Product at issue.
`
`11.
`
`On information and belief, following any FDA approval of ANDA No.
`
`208334, Micro Labs Ltd. and Micro Labs USA Inc. will act in concert to market, distribute, offer
`
`for sale, and sell Micro Labs’ ANDA Product throughout the United States and within Delaware.
`
`These two entities are hereafter collectively referred to as “Micro Labs.”
`
`3
`
`
`
`Case 1:22-cv-00165-UNA Document 1 Filed 02/04/22 Page 4 of 11 PageID #: 4
`
`
`
`12.
`
`On information and belief, following any FDA approval of ANDA No.
`
`208334, Micro Labs will market, distribute, offer for sale, and sell Micro Labs’ ANDA Product
`
`throughout the United States and within Delaware.
`
`13.
`
`On information and belief, following any FDA approval of ANDA No.
`
`208334, Micro Labs knows and intends that its ANDA Product will be marketed, used, distributed,
`
`offered for sale, and sold in the United States and within Delaware.
`
`JURISDICTION
`
`14.
`
`Plaintiffs incorporate each of the preceding paragraphs as if fully set forth
`
`herein.
`
`15.
`
`This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331,
`
`1338(a), 2201, and 2202.
`
`16.
`
`In addition, this Court has personal jurisdiction over Micro Labs because,
`
`among other things, on information and belief: (1) Micro Labs has filed an ANDA for the purpose
`
`of seeking approval to engage in the commercial manufacture, use, offer for sale, sale, and/or
`
`importation of Micro Labs’ ANDA Product in the United States, including in Delaware; and
`
`(2) Micro Labs will market, distribute, offer for sale, and/or sell Micro Labs’ ANDA Product in
`
`the United States, including in Delaware, upon approval of ANDA No. 208334, and will derive
`
`substantial revenue from the use or consumption of Micro Labs’ ANDA Product in the State of
`
`Delaware. On information and belief, if ANDA No. 208334 is approved, the generic Micro Labs
`
`product charged with infringing the ’310 patent would, among other things, be marketed,
`
`distributed, offered for sale, and/or sold in Delaware, prescribed by physicians practicing in
`
`Delaware, and dispensed by pharmacies located within Delaware, and/or used by patients in
`
`Delaware, all of which would have a substantial effect on Delaware.
`
`4
`
`
`
`Case 1:22-cv-00165-UNA Document 1 Filed 02/04/22 Page 5 of 11 PageID #: 5
`
`
`
`17.
`
`Alternatively, if Micro Labs Ltd.’s connections with Delaware are found to
`
`be insufficient to confer personal jurisdiction, then, upon information and belief, Micro Labs Ltd.
`
`is not subject to jurisdiction in any state’s courts of general jurisdiction, and exercising jurisdiction
`
`over Micro Labs Ltd. in Delaware is consistent with the United States Constitution and laws. See
`
`Fed. R. Civ. P. 4(k)(2).
`
`18. Micro Labs has consented to personal jurisdiction in Delaware in one or
`
`more prior cases arising out of the filing of its ANDAs, including C.A. Nos. 16-cv-00242 and 17-
`
`cv-00560, and it has filed counterclaims in such cases. In addition, upon information and belief,
`
`Micro Labs will consent to personal jurisdiction in Delaware for purposes of this action.
`
`VENUE
`
`19.
`
`Venue is proper in this district for Micro Labs Ltd. pursuant to 28 U.S.C.
`
`§§ 1391 and 1400(b) because, inter alia, Micro Labs Ltd. is a company organized and existing
`
`under the laws of India and is subject to personal jurisdiction in this judicial district.
`
`20.
`
`Venue is proper in this district for Micro Labs USA pursuant to 28 U.S.C.
`
`§§ 1391 and 1400(b) because, inter alia, Micro Labs USA is subject to personal jurisdiction in this
`
`judicial district, has previously consented to venue in this judicial district, and will consent to
`
`venue in this judicial district for purposes of this action.
`
`FACTUAL BACKGROUND
`
`21.
`
`XARELTO® (active ingredient rivaroxaban) is a factor Xa inhibitor. The
`
`2.5 mg tablet strength of XARELTO® is indicated for administration orally twice daily, in
`
`combination with aspirin (75-100 mg) once daily, to reduce the risk of major cardiovascular events
`
`(cardiovascular (CV) death, myocardial infarction (MI), and stroke) in patients with chronic
`
`coronary artery disease (CAD) or peripheral artery disease (PAD).
`
`5
`
`
`
`Case 1:22-cv-00165-UNA Document 1 Filed 02/04/22 Page 6 of 11 PageID #: 6
`
`
`
`22.
`
`Janssen is the holder of New Drug Application No. 022406 for
`
`XARELTO®, which has been approved by the FDA.
`
`23.
`
`The ’310 patent, entitled “Reducing the Risk of Cardiovascular Events,”
`
`was duly and legally issued on November 10, 2020. The ’310 patent is attached as Exhibit A.
`
`24.
`
`As set forth in greater detail in the ’310 patent, the claims of the ’310 patent,
`
`incorporated by reference herein, cover certain methods involving rivaroxaban. For example,
`
`independent claim 1 recites, “A method of reducing the risk of myocardial infarction, stroke or
`
`cardiovascular death in a human patient with coronary artery disease and/or peripheral artery
`
`disease, comprising administering to the human patient rivaroxaban and aspirin in amounts that
`
`are clinically proven effective in reducing the risk of myocardial infarction, stroke or
`
`cardiovascular death in a human patient with coronary artery disease and/or peripheral arterial
`
`disease, wherein rivaroxaban is administered in an amount of 2.5 mg twice daily and aspirin is
`
`administered in an amount of 75-100 mg daily.”
`
`25.
`
`26.
`
`27.
`
`28.
`
`Bayer Pharma AG is the assignee of the ’310 patent.
`
`Bayer AG is an exclusive licensee under the ’310 patent.
`
`Janssen is an exclusive sublicensee under the ’310 patent.
`
`Pursuant to 21 U.S.C. § 355, the ’310 patent is listed in Approved Drug
`
`Products with Therapeutic Equivalence Evaluations (“the Orange Book”) in connection with the
`
`2.5 mg strength of XARELTO®.
`
`COUNT I: INFRINGEMENT OF THE ’310 PATENT
`
`29.
`
`Plaintiffs incorporate each of the preceding paragraphs as if fully set forth
`
`herein.
`
`6
`
`
`
`Case 1:22-cv-00165-UNA Document 1 Filed 02/04/22 Page 7 of 11 PageID #: 7
`
`
`
`30.
`
`By letter dated December 29, 2021 (the “Micro Labs Notice Letter”), Micro
`
`Labs notified, inter alia, Bayer Pharma AG and Janssen that Micro Labs had submitted to the FDA
`
`ANDA No. 208334 for Micro Labs’ ANDA Product and had submitted an amendment to that
`
`ANDA. This product is a generic version of the 2.5 mg strength of XARELTO®.
`
`31.
`
`In the Micro Labs Notice Letter, Micro Labs indicated that, in connection
`
`with its ANDA No. 208334, Micro Labs had filed, inter alia, a Paragraph IV Certification with
`
`respect to the ’310 patent.
`
`32.
`
`In the Micro Labs Notice Letter, Micro Labs stated that Micro Labs’ ANDA
`
`Product contains rivaroxaban.
`
`33.
`
`On information and belief, the proposed labeling for Micro Labs’ ANDA
`
`Product directs a method of reducing the risk of major cardiovascular events (cardiovascular (CV)
`
`death, myocardial infarction (MI), and stroke) in patients with chronic coronary artery disease
`
`(CAD) or peripheral artery disease (PAD). On information and belief, the proposed labeling for
`
`Micro Labs’ ANDA Product further directs the administration of Micro Labs’ ANDA Product and
`
`aspirin in amounts that are clinically proven effective in reducing the risk of MI, stroke or CV
`
`death in a human patient with CAD and/or PAD, wherein Micro Labs’ ANDA Product will be
`
`administered twice daily and aspirin is administered in an amount of 75-100 mg daily.
`
`34.
`
`The purpose of ANDA No. 208334 was, inter alia, to obtain approval under
`
`the Federal Food, Drug, and Cosmetic Act to engage in the commercial manufacture, use, offer
`
`for sale, and/or sale of Micro Labs’ ANDA Product with its proposed labeling prior to the
`
`expiration of the ’310 patent.
`
`35. Micro Labs intends to engage in the manufacture, use, offer for sale, sale,
`
`marketing, distribution, and/or importation of Micro Labs’ ANDA Product with its proposed
`
`7
`
`
`
`Case 1:22-cv-00165-UNA Document 1 Filed 02/04/22 Page 8 of 11 PageID #: 8
`
`
`
`labeling immediately and imminently upon approval of ANDA No. 208334, i.e., prior to the
`
`expiration of the ’310 patent.
`
`36.
`
`On information and belief, the manufacture, use (including in accordance
`
`with and as directed by Micro Labs’ proposed labeling for Micro Labs’ ANDA Product), offer for
`
`sale, sale, marketing, distribution, and/or importation of Micro Labs’ ANDA Product will infringe
`
`at least claim 1 of the ’310 patent.
`
`37. Micro Labs has knowledge of
`
`the claims of
`
`the ’310 patent.
`
`Notwithstanding this knowledge, Micro Labs has continued to assert its intent to engage in the
`
`manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of Micro Labs’
`
`ANDA Product with its proposed labeling immediately and imminently upon approval of ANDA
`
`No. 208334. On information and belief, by such activities, Micro Labs specifically intends to
`
`infringe the ’310 patent.
`
`38.
`
`On information and belief, Micro Labs plans and intends to, and will,
`
`actively induce infringement of the ’310 patent when its ANDA is approved, and plans and intends
`
`to, and will, do so immediately and imminently upon approval.
`
`39.
`
`On information and belief, Micro Labs knows that Micro Labs’ ANDA
`
`Product with its proposed labeling is especially made or adapted for use in infringing the ’310
`
`patent, and that Micro Labs’ ANDA Product with its proposed labeling is not suitable for
`
`substantial noninfringing use. On information and belief, Micro Labs plans and intends to, and
`
`will, contribute to infringement of the ’310 patent immediately and imminently upon approval of
`
`ANDA No. 208334.
`
`40. Micro Labs’ submission of ANDA No. 208334 and submission of an
`
`amendment to that ANDA for the purpose of obtaining approval to engage in the commercial
`
`8
`
`
`
`Case 1:22-cv-00165-UNA Document 1 Filed 02/04/22 Page 9 of 11 PageID #: 9
`
`
`
`manufacture, use, offer for sale, and/or sale of Micro Labs’ ANDA Product were acts of
`
`infringement of the ’310 patent under 35 U.S.C. § 271(e)(2).
`
`41.
`
`On information and belief, Micro Labs has made, and will continue to make,
`
`substantial preparation in the United States to manufacture, use, sell, offer to sell, and/or import
`
`Micro Labs’ ANDA Product with its proposed labeling prior to the expiration of the ’310 patent.
`
`42. Micro Labs intends to engage in the manufacture, use, offer for sale, sale,
`
`marketing, distribution, and/or importation of Micro Labs’ ANDA Product with its proposed
`
`labeling prior to the expiration of the ’310 patent.
`
`43.
`
`The foregoing actions by Micro Labs constitute and/or will constitute
`
`infringement of the ’310 patent, active inducement of infringement of the ’310 patent, and/or
`
`contribution to the infringement by others of the ’310 patent.
`
`44.
`
`Unless Micro Labs is enjoined from infringing the ’310 patent, actively
`
`inducing infringement of the ’310 patent, and contributing to the infringement by others of the
`
`’310 patent, Plaintiffs will suffer irreparable injury. Plaintiffs have no adequate remedy at law.
`
`45.
`
`This action is being commenced before the expiration of forty-five days
`
`from the date Bayer and Janssen received the Micro Labs Notice Letter.
`
`COUNT II: DECLARATORY JUDGMENT OF INFRINGEMENT
`OF THE ’310 PATENT
`
`46.
`
`Plaintiffs incorporate each of the preceding paragraphs as if fully set forth
`
`herein.
`
`47.
`
`The Court may declare the rights and legal relations of the parties pursuant
`
`to 28 U.S.C. §§ 2201 and 2202 because there is a case of actual controversy between Plaintiffs on
`
`the one hand and Micro Labs on the other regarding Micro Labs’ liability for infringement and
`
`active inducement of infringement of the ’310 patent.
`
`9
`
`
`
`Case 1:22-cv-00165-UNA Document 1 Filed 02/04/22 Page 10 of 11 PageID #: 10
`
`
`
`48.
`
`An actual case or controversy exists between Plaintiffs and Micro Labs with
`
`respect to Micro Labs’ liability for infringement of the ’310 patent.
`
`49.
`
`The Court should declare that the commercial manufacture, use, sale, offer
`
`for sale or importation of Micro Labs’ ANDA Product will infringe and induce the infringement
`
`of the ’310 patent.
`
`* * *
`
`WHEREFORE, Plaintiffs request the following relief:
`
`(a)
`
`(b)
`
`A judgment that Micro Labs has infringed the ’310 patent;
`
`A judgment ordering that the effective date of any FDA approval for Micro
`
`Labs to make, use, offer for sale, sell, market, distribute, or import Micro Labs’ ANDA Product,
`
`or any product or compound the use of which infringes the ’310 patent, be no earlier than the
`
`expiration date of the ’310 patent, inclusive of any extension(s) and additional period(s) of
`
`exclusivity;
`
`(c)
`
`A preliminary and permanent injunction enjoining Micro Labs, and all
`
`persons acting in concert with Micro Labs, from making, using, selling, offering for sale,
`
`marketing, distributing, or importing Micro Labs’ ANDA Product, or any product or compound
`
`the use of which infringes the ’310 patent, or the inducement of or the contribution to any of the
`
`foregoing, prior to the expiration date of the ’310 patent, inclusive of any extension(s) and
`
`additional period(s) of exclusivity;
`
`(d)
`
`A judgment declaring that the commercial manufacture, use, sale, offer for
`
`sale or importation of Micro Labs’ ANDA Product prior to the expiration of the ’310 patent will
`
`infringe and induce the infringement of the ’310 patent;
`
`10
`
`
`
`Case 1:22-cv-00165-UNA Document 1 Filed 02/04/22 Page 11 of 11 PageID #: 11
`
`
`
`(e)
`
`A declaration that this is an exceptional case and an award of attorneys’ fees
`
`for Plaintiffs pursuant to 35 U.S.C. § 285;
`
`(f)
`
`(g)
`
`An award of Plaintiffs’ costs and expenses in this action; and
`
`Such further and other relief as this Court may deem just and proper.
`
`
`
`
`
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`
`/s/ Jack B. Blumenfeld
`
`
`
`
`Jack B. Blumenfeld (#1014)
`Rodger D. Smith (#3778)
`Derek J. Fahnestock (#4705)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@morrisnichols.com
`rsmith@morrisnichols.com
`dfahnestock@morrisnichols.com
`
`Attorneys for Plaintiffs Bayer Pharma AG,
`Bayer AG and Janssen Pharmaceuticals, Inc.
`
`
`
`
`
`
`
`
`
`OF COUNSEL:
`
`Bruce R. Genderson
`Dov P. Grossman
`Alexander S. Zolan
`Kathryn S. Kayali
`Julie L. Tavares
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street NW
`Washington, DC 20005
`(202) 434-5000
`
`Attorneys for Plaintiffs Bayer Pharma AG and
`Bayer AG
`
`Thomas D. Rein
`SIDLEY AUSTIN LLP
`One South Dearborn
`Chicago, IL 60603
`(312) 853-7000
`
`Andrew T. Langford
`SIDLEY AUSTIN LLP
`2021 McKinney Avenue, Suite 2000
`Dallas, TX 75201
`(214) 981-3300
`
`Attorneys for Plaintiff Janssen
`Pharmaceuticals, Inc.
`
`February 4, 2022
`
`11
`
`